We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Surgery Still Best for Varicose Veins

By HospiMedica staff writers
Posted on 06 Dec 2006
A new study has found that traditional open surgery is still the superior ablation technique for the great saphenous vein, compared to newer alternatives. More...


Researchers from Imperial College London (UK) compared traditional open surgery to newer alternatives. While traditional open surgery has been performed for over a century, alternative ablation treatments for varicose veins such as endovenous laser ablation, radiofrequency ablation, and foam sclerotherapy have only been in use for 10 years. The limited medical literature available for newer procedures makes comparing recurrence rates difficult. The longest study of endovenous laser ablation available covers only 39 months. Radiofrequency ablation is better documented; a recent three-year study showed it had a significantly worse recurrence rate of 33% as compared to traditional open surgery, which showed a rate of only 23%.

Traditional open surgery is a well-studied procedure, and generally needs to be performed only once. General complications include deep vein thrombosis (0.15%), pulmonary embolus (0.06%), and wound complication, including infection (2.2%).
General complications for radiofrequency ablation include bruising, burns, paraesthesia, clinical phlebitis, and slightly higher rates of deep vein thrombosis (0.57%) and pulmonary embolus (0.17%) than occur after open surgery. Endovenous laser ablation is associated with similar complications, including bruising (24-100%), burns (4.8%), paraesthesia (1-36.5%), and induration along the length of the saphenous vein (55-100%). The findings were presented at the 33rd annual Veith symposium, held in November 2006 in New York (NY, USA).

"The jury remains out on the optimal way in which to treat patients presenting with primary venous incompetence; the endo-luminal techniques definitely have complications,” said lead author Dr. Alun H. Davies. "The long-term recurrence rates have yet to be properly compared between the different modalities.”

The authors found that these facts strongly suggest that newer endovascular procedures should be more thoroughly studied and compared with traditional open surgery, and that the best clinical practice is to empower patients with the information that they need to make a choice among them.



Related Links:
Imperial College London

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.